Do you have a policy for the handling of incidental findings in clinical trial medical images?

How companies are handling incidental findings in the medical images they obtain during clinical trials is a hot topic in the medical imaging competitive landscape.

Innovative medical imaging such as positron emission tomography (PET), Optical Coherance Tomography (OCT) and Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) are now widely used in clinical trials, and have opened the door to new ways to visualize joints, blood vessels, organs and tumors.

However, in the process, these clinical trial medical images are generating “incidental findings” (IF).

For further analysis read the post published on Biotech Strategy Blog.

, , , , , ,

error: Content is protected !!